Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962904 | 0.89 | OPRM1 (0.37) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL45963 | 0.89 | OPRM1 (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14292473 | 0.87 | OPRM1 (0.38) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL12337175 | 0.82 | HCRTR1 (0.40) | — | |
| SCHEMBL13379143 | 0.81 | OPRM1 (0.33) | OPRM1OPRD1OPRK1 | |
| SCHEMBL46027 | 0.80 | — | — | |
| SCHEMBL14202054 | 0.80 | KDM1A (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13847988 | 0.79 | OPRM1 (0.38) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13847996 | 0.79 | OPRM1 (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13660037 | 0.78 | OPRM1 (0.35) | OPRM1OPRD1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302594-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263807-B2 | Quaternary opioid carboxamides | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100197921-A1 | Preparation of N-Alkylated Opiates by Reductive Amination | MALLINCKRODT ENTERPRISES LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010039222-A2 | PROCESSES FOR THE SELECTIVE AMINATION OF KETOMORPHINANS | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197921-A1 | Preparation of N-Alkylated Opiates by Reductive Amination | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885OPRK1 3/4885 |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20120302594-A1 | QUATERNARY OPIOID CARBOXAMIDES | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.